Nurx Review: Prescribing Data, Outcomes Signals, and What Women Really Need to Know

Is Nurx Legit? The Short Answer, With Caveats

Nurx meets the basic regulatory floor for a U.S. Online pharmacy. The platform holds LegitScript certification, which requires proof of state licensure, a valid pharmacy dispensing agreement, and prescriber credentials. Its pharmacy partners must comply with FDA regulations governing controlled and non-controlled prescription drugs. That means Nurx is not operating in the gray market that governs some offshore pill-mail services.

What "legit" does not mean: that every prescribing decision is optimal for every woman, that wait times are acceptable, or that the asynchronous care model suits complex hormonal cases. Those are separate questions, and the answers are more mixed.

How Nurx Is Licensed

Nurx operates under a distributed-prescriber model. Clinicians are licensed in the states where patients reside, not in one central hub. State medical boards govern telehealth prescribing standards, and rules differ substantially. For example, the Federation of State Medical Boards' telehealth policy requires an established patient-provider relationship before prescribing certain drug classes, though asynchronous questionnaire-based encounters still satisfy that standard in most states for non-controlled medications like combined oral contraceptives.

What the BBB Data Actually Shows

The Better Business Bureau shows Nurx carrying a B+ rating with more than 200 complaints closed in the prior three years as of mid-2025. The most common complaint categories cluster around billing disputes, prescription delays, and difficulty reaching a clinician for follow-up questions. A smaller subset describes clinical concerns: women reporting that contraindications were not adequately screened, or that their prescription was renewed without any clinical reassessment.

Complaints are not outcomes data. They represent a self-selected group of dissatisfied users. Nurx has reportedly served over one million patients, so a complaint rate below 0.02% is not alarming in isolation. The pattern of complaint type matters more than raw count.

What Nurx Prescribes: A Women's-Health Map by Life Stage

Nurx started as a birth-control-only platform and has expanded considerably. Here is what the service covers, mapped to the life stage where it is most relevant.

Reproductive Years (Ages Roughly 18 to 40)

Birth control is Nurx's core product. The platform prescribes combined oral contraceptives (COCs), progestin-only pills, the patch, the vaginal ring, and emergency contraception. It does not insert IUDs or implants (those require an in-office procedure), which is a meaningful gap for women who want the most effective long-acting reversible options.

ACOG Practice Bulletin No. 206 on combined hormonal contraceptives identifies venous thromboembolism (VTE) risk as the primary safety concern with COCs, with an absolute risk of roughly 3 to 9 per 10,000 woman-years in COC users compared to 1 to 5 per 10,000 in non-users. A thorough pre-prescribing screen for personal or family history of clotting disorders, migraine with aura, uncontrolled hypertension, and smoking status is therefore not optional. Nurx's intake questionnaire covers these items, but an asynchronous text-based intake is not equivalent to a clinical conversation for a woman with a complex history.

Hormonal acne is another reproductive-years condition where Nurx prescribes. COCs containing norgestimate or drospirenone have FDA-approved acne indications, and spironolactone is frequently co-prescribed off-label for androgenic acne. Nurx offers both. Women with PCOS-related acne and hirsutism overlap heavily with this group. Spironolactone requires potassium monitoring at baseline and at dose changes; whether that lab ordering is consistently executed in a fully asynchronous model is a legitimate clinical question Nurx has not publicly answered with outcomes data.

UTI treatment is a newer Nurx service line. Empiric antibiotic prescribing for uncomplicated urinary tract infections without a urine culture is supported by ACOG and the Infectious Diseases Society of America for uncomplicated lower UTI in otherwise healthy, non-pregnant women, but the key exclusion is pregnancy. A woman in early pregnancy who mistakes urinary symptoms for a routine UTI and obtains antibiotics without pregnancy screening faces real risk. The adequacy of Nurx's pregnancy-exclusion workflow for this service has not been independently audited in published literature.

Trying to Conceive and Fertility-Adjacent Care

Nurx does not offer fertility evaluation, ovulation induction, or IVF coordination. Women who are actively trying to conceive should not be using Nurx-prescribed COCs or hormonal contraceptives, which is self-evident, but the platform's intake process for women transitioning from contraception to conception planning has not been publicly described in detail. Women stopping COCs to try to conceive should be counseled that return of fertility after COC discontinuation is typically prompt with most women ovulating within one to three months, though menstrual cycle regularization may take longer in women with underlying PCOS.

Perimenopause (Roughly Ages 40 to 52)

Nurx has expanded into HRT for perimenopause and menopause, a move that mirrors broader telehealth growth in this space. This is where the clinical stakes rise considerably.

The Menopause Society's 2023 position statement on hormone therapy is the governing U.S. Clinical standard. It supports HRT for bothersome vasomotor symptoms in healthy women under 60 or within 10 years of menopause onset, with the benefit-risk profile shifting at older ages and longer durations. Nurx's HRT service prescribes FDA-approved estrogen and progesterone formulations. Whether its intake process reliably identifies women for whom HRT carries elevated risk (personal history of breast cancer, unexplained vaginal bleeding, active DVT, or liver disease) is not documented in any published audit.

A perimenopausal woman should know that estradiol levels fluctuate dramatically during the menopausal transition, making symptom-based prescribing more complex than in post-menopause. An asynchronous questionnaire may miss the cycling nature of perimenopausal symptoms and lead to dose decisions that would benefit from a synchronous visit.

Post-Menopause

Post-menopausal women using Nurx for HRT continuation or initiation face the standard benefit-risk calculus described in The Menopause Society's 2023 guidance. The absolute cardiovascular and breast cancer risks differ by age, formulation, and duration. A 55-year-old woman who is five years post-menopause initiating HRT has a meaningfully different risk profile than a 68-year-old initiating de novo. Nurx's platform should, in principle, distinguish these cases. There is no published data confirming it consistently does.

Genitourinary syndrome of menopause (GSM), which affects roughly 50 to 70 percent of post-menopausal women, is another area where Nurx prescribes vaginal estrogen. Vaginal estrogen has a favorable safety profile even in women with a history of breast cancer in some guidelines, though that nuance requires careful clinical judgment. A telehealth asynchronous platform prescribing vaginal estrogen to a breast-cancer survivor without oncologist coordination would be a serious gap.

Pregnancy and Lactation: The Non-Negotiable Safety Section

Every drug category Nurx prescribes has specific pregnancy and lactation considerations. Women using Nurx need to understand these before any prescription is filled.

Combined Oral Contraceptives

COCs are not teratogenic in exposures that occur before a recognized pregnancy. However, COCs must be discontinued once pregnancy is confirmed. Estrogen-containing contraceptives are contraindicated in the postpartum period for women who are breastfeeding during the first 30 days postpartum, and should be used cautiously between 30 and 42 days postpartum, per CDC Medical Eligibility Criteria for Contraceptive Use (US MEC). Progestin-only pills are the preferred hormonal option for lactating women.

Spironolactone

Spironolactone is contraindicated in pregnancy. It has antiandrogenic properties that may cause feminization of a male fetus. The FDA pregnancy labeling categorizes it as posing fetal risk. Any woman of reproductive age receiving spironolactone from Nurx should be using a reliable contraceptive method concurrently. This is a requirement that must be stated explicitly at prescribing, not buried in intake text. Spironolactone transfers into breast milk; breastfeeding is generally not recommended while taking it, though published lactation data is limited.

Hormonal HRT Formulations

Systemic estrogen and progestogen therapy is contraindicated in pregnancy. A woman in perimenopause who has not confirmed menopause may still have residual fertility, and HRT is not a contraceptive. Women in perimenopause using HRT should use a separate contraceptive method until menopause is confirmed (typically defined as 12 consecutive months of amenorrhea). ACOG guidance on contraception in the perimenopause addresses this directly. Nurx's HRT intake should flag this, and women should verify that it does before proceeding.

Vaginal Estrogen

Low-dose vaginal estrogen has minimal systemic absorption. The Menopause Society and ACOG consider it low-risk for most post-menopausal women. It is not indicated in pregnancy. Lactation safety data are insufficient for strong recommendations.

Antibiotics for UTI

Nitrofurantoin and trimethoprim-sulfamethoxazole (common UTI antibiotic choices) carry pregnancy-specific restrictions. Nitrofurantoin is avoided at term (38 to 42 weeks gestation) due to risk of neonatal hemolytic anemia. Trimethoprim-sulfamethoxazole is avoided in the first trimester (folate antagonism) and near term. These restrictions make pregnancy exclusion absolutely necessary before empiric antibiotic prescribing for UTI symptoms.

PCOS, Endometriosis, and Other Female-Specific Conditions

Nurx prescribes for some female-specific conditions but not others. The gaps matter.

PCOS: COCs and spironolactone are first-line medical therapies for the menstrual and androgenic manifestations of PCOS. Nurx can prescribe both. What Nurx does not do is screen for insulin resistance, order an androgen panel, or coordinate with an endocrinologist. For a woman with mild PCOS-related acne and irregular cycles, Nurx may be sufficient. For a woman with metabolic PCOS, elevated androgens, or fertility goals, it is not a complete care solution.

Endometriosis: Nurx does not diagnose or manage endometriosis in any meaningful clinical sense. Continuous COC use to suppress menstruation is sometimes used symptomatically, and Nurx can prescribe that. It cannot coordinate the surgical diagnosis, the specialist follow-up, or the progestogen-based second-line therapies that comprehensive endometriosis management requires.

Female pattern hair loss: Spironolactone is used off-label for androgenic alopecia in women. Nurx prescribes it. The same pregnancy contraindication applies.

Prescribing Data and Outcomes Signals: What Is Actually Published

This is where the evidence base is thinnest, and intellectual honesty requires saying so directly.

No peer-reviewed outcomes study using Nurx patient data has been published in a major journal as of mid-2025. This is not unique to Nurx. The telehealth birth control space broadly lacks rigorous published outcomes data. A 2021 analysis in JAMA Internal Medicine examined telehealth contraceptive prescribing and found that asynchronous, questionnaire-based models had comparable contraindication-screening performance to in-person visits for low-complexity patients, but the study was not Nurx-specific and did not capture rare adverse events.

The FDA's MedWatch database is a public adverse-event signal source, but reports are not systematically tagged by prescribing platform, making it impossible to isolate Nurx-specific safety signals.

What can be said: the drugs Nurx prescribes (COCs, spironolactone, estradiol, progesterone, nitrofurantoin) have well-characterized population-level safety profiles from decades of data. The question is whether an asynchronous telehealth intake captures enough clinical context to apply those population-level safety data appropriately to individual women. Published evidence on that specific question, for Nurx specifically, does not yet exist.

Women have been historically underrepresented in clinical trials, and telehealth-specific outcomes data for women using these platforms is even thinner. This gap matters because the women most likely to use telehealth (those with transportation barriers, demanding work schedules, or limited access to in-person specialists) may also be those with higher baseline complexity.

Who Nurx Is Right for, and Who Should Pause

Good candidates for Nurx

A woman who is a good candidate for Nurx tends to share several characteristics. She is in good general health, has already been screened in-person at some point, and needs a straightforward prescription renewed or initiated without complicating history. Specifically:

• A healthy woman aged 18 to 40 needing COC renewal who has no history of VTE, migraine with aura, clotting disorders, or hepatic disease
• A post-menopausal woman with straightforward GSM symptoms who has had a recent in-person gynecologic evaluation
• A woman with a known, uncomplicated UTI pattern (not first episode, no complicating features, confirmed non-pregnant)
• A woman in perimenopause with vasomotor symptoms and no personal history of hormone-sensitive cancer or cardiovascular disease, who wants HRT and has recent bloodwork available

Women who should pause or seek in-person care first

• Any woman who is pregnant, possibly pregnant, or actively trying to conceive (multiple Nurx drug categories are contraindicated)
• Women with a personal history of breast cancer, DVT, pulmonary embolism, or stroke
• Women with migraine with aura (combined hormonal contraceptives are contraindicated per WHO Medical Eligibility Criteria, Category 4)
• Women with PCOS who need metabolic evaluation alongside hormonal management
• Women with endometriosis requiring surgical or specialist-coordinated care
• Women with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg), a WHO MEC Category 4 contraindication for COCs
• Perimenopausal women who are unsure about their pregnancy status and are initiating HRT

The Complaint Pattern: What Women Report

The BBB complaint record for Nurx is publicly searchable. Beyond billing disputes, three clinical patterns appear with enough frequency to warrant attention.

First, women report difficulty getting a response when they experience a side effect and need clinical guidance. An asynchronous model that works well for routine renewals may leave a woman who develops breakthrough bleeding, mood changes, or elevated blood pressure without a timely answer.

Second, some women report prescriptions being renewed without any clinical reassessment. COC renewals, in particular, should include periodic blood pressure screening. ACOG guidance recommends blood pressure measurement before initiation and at three months, then annually. Whether Nurx consistently prompts this in a remote-only model is not clear.

Third, a subset of complaints describes insurance billing practices: charges appearing differently than expected, or difficulty obtaining itemized receipts for FSA or HSA reimbursement. This is an administrative rather than clinical concern, but it affects real women managing real health care costs.

How to Use Nurx Safely: A Practical Checklist

If you decide to use Nurx, these steps reduce your risk of a gap in care.

1. Confirm your own non-pregnant status before initiating any prescription, especially spironolactone, systemic HRT, or antibiotics.
2. Have a record of your most recent blood pressure reading before starting COCs. Take your blood pressure at a pharmacy if you do not have a home cuff.
3. Disclose your complete medication list in the intake, including supplements. Drug interactions are not always flagged in asynchronous systems.
4. Request a synchronous video visit if your history is complex. Nurx offers this; use it.
5. Know the red flags that require in-person care, not a message to a telehealth platform: chest pain, leg pain and swelling, vision changes, severe headache, or any symptom that suggests a VTE or stroke.
6. Keep your in-person primary care provider or gynecologist informed. Nurx should supplement, not replace, your established care relationships.